Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00823212
Registration number
NCT00823212
Ethics application status
Date submitted
13/01/2009
Date registered
15/01/2009
Titles & IDs
Public title
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions
Query!
Scientific title
PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions
Query!
Secondary ID [1]
0
0
ACTRN12608000582358
Query!
Secondary ID [2]
0
0
S2046
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PLATINUM
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Coronary Artery Disease
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - PROMUS Coronary Stent System
Treatment: Devices - PROMUS Element Coronary Stent System
Treatment: Drugs - Aspirin
Treatment: Drugs - Thienopyridine
Active comparator: PROMUS - Patients who received the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent
Experimental: PROMUS Element - Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
Treatment: Devices: PROMUS Coronary Stent System
PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
Treatment: Devices: PROMUS Element Coronary Stent System
PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS \[XIENCE V\] stent).
Treatment: Drugs: Aspirin
Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
Treatment: Drugs: Thienopyridine
Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Target Lesion Failure (TLF)
Query!
Assessment method [1]
0
0
Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Query!
Timepoint [1]
0
0
12-month post index procedure
Query!
Secondary outcome [1]
0
0
Target Lesion Failure (TLF)
Query!
Assessment method [1]
0
0
TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Query!
Timepoint [1]
0
0
30 days
Query!
Secondary outcome [2]
0
0
Target Lesion Failure (TLF)
Query!
Assessment method [2]
0
0
TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Query!
Timepoint [2]
0
0
6 months
Query!
Secondary outcome [3]
0
0
Target Lesion Failure (TLF)
Query!
Assessment method [3]
0
0
TLF is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.
Query!
Timepoint [3]
0
0
12 months
Query!
Secondary outcome [4]
0
0
Target Vessel Failure (TVF)
Query!
Assessment method [4]
0
0
TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Query!
Timepoint [4]
0
0
30 days
Query!
Secondary outcome [5]
0
0
Target Vessel Failure (TVF)
Query!
Assessment method [5]
0
0
TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Query!
Timepoint [5]
0
0
6 months
Query!
Secondary outcome [6]
0
0
Target Vessel Failure (TVF)
Query!
Assessment method [6]
0
0
TVF is defined as any ischemia-driven revascularization of the target vessel, MI (Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.
Query!
Timepoint [6]
0
0
12 months
Query!
Secondary outcome [7]
0
0
Myocardial Infarction (MI) Related to the Target Vessel
Query!
Assessment method [7]
0
0
Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) \>3x normal (peri-percutaneous coronary intervention \[PCI\]) or \>2x normal (spontaneous) with elevated CK-MB, or troponin \>3x normal (peri-PCI) or \>2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin \>5x normal
Query!
Timepoint [7]
0
0
30 days
Query!
Secondary outcome [8]
0
0
Myocardial Infarction (MI) Related to the Target Vessel
Query!
Assessment method [8]
0
0
Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) \>3x normal (peri-percutaneous coronary intervention \[PCI\]) or \>2x normal (spontaneous) with elevated CK-MB, or troponin \>3x normal (peri-PCI) or \>2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin \>5x normal
Query!
Timepoint [8]
0
0
6 months
Query!
Secondary outcome [9]
0
0
Myocardial Infarction (MI) Related to the Target Vessel
Query!
Assessment method [9]
0
0
Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) \>3x normal (peri-percutaneous coronary intervention \[PCI\]) or \>2x normal (spontaneous) with elevated CK-MB, or troponin \>3x normal (peri-PCI) or \>2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin \>5x normal
Query!
Timepoint [9]
0
0
12 months
Query!
Secondary outcome [10]
0
0
All Cause Mortality
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
30 days
Query!
Secondary outcome [11]
0
0
All Cause Mortality
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
6 months
Query!
Secondary outcome [12]
0
0
All Cause Mortality
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
12 months
Query!
Secondary outcome [13]
0
0
Cardiac Death Related to the Target Vessel
Query!
Assessment method [13]
0
0
Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Query!
Timepoint [13]
0
0
30 days
Query!
Secondary outcome [14]
0
0
Cardiac Death Related to the Target Vessel
Query!
Assessment method [14]
0
0
Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Query!
Timepoint [14]
0
0
6 months
Query!
Secondary outcome [15]
0
0
Cardiac Death Related to the Target Vessel
Query!
Assessment method [15]
0
0
Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded
Query!
Timepoint [15]
0
0
12 months
Query!
Secondary outcome [16]
0
0
Non-cardiac Death
Query!
Assessment method [16]
0
0
Defined as a death not due to cardiac causes (see definition of cardiac death above)
Query!
Timepoint [16]
0
0
30 Days
Query!
Secondary outcome [17]
0
0
Non-cardiac Death
Query!
Assessment method [17]
0
0
Defined as a death not due to cardiac causes (see definition of cardiac death above)
Query!
Timepoint [17]
0
0
6 Months
Query!
Secondary outcome [18]
0
0
Non-cardiac Death
Query!
Assessment method [18]
0
0
Defined as a death not due to cardiac causes (see definition of cardiac death above)
Query!
Timepoint [18]
0
0
12 months
Query!
Secondary outcome [19]
0
0
Cardiac Death or Myocardial Infarction (MI)
Query!
Assessment method [19]
0
0
Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Query!
Timepoint [19]
0
0
30 days
Query!
Secondary outcome [20]
0
0
Cardiac Death or Myocardial Infarction (MI)
Query!
Assessment method [20]
0
0
Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Query!
Timepoint [20]
0
0
6 months
Query!
Secondary outcome [21]
0
0
Cardiac Death or Myocardial Infarction (MI)
Query!
Assessment method [21]
0
0
Cardiac death is defined as Death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above
Query!
Timepoint [21]
0
0
12 months
Query!
Secondary outcome [22]
0
0
All Death or Myocardial Infarction (MI)
Query!
Assessment method [22]
0
0
Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) \>3x normal (peri-percutaneous coronary intervention \[PCI\]) or \>2x normal (spontaneous) with elevated CK-MB, or troponin \>3x normal (peri-PCI) or \>2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin \>5x normal
Query!
Timepoint [22]
0
0
30 days
Query!
Secondary outcome [23]
0
0
All Death or Myocardial Infarction (MI)
Query!
Assessment method [23]
0
0
Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) \>3x normal (peri-percutaneous coronary intervention \[PCI\]) or \>2x normal (spontaneous) with elevated CK-MB, or troponin \>3x normal (peri-PCI) or \>2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin \>5x normal
Query!
Timepoint [23]
0
0
6 months
Query!
Secondary outcome [24]
0
0
All Death or Myocardial Infarction (MI)
Query!
Assessment method [24]
0
0
Development of new Q-waves in =2 leads lasting =0.04 seconds with CK-MB/troponin levels above normal; if no new Q-waves, total creatine kinase (CK) \>3x normal (peri-percutaneous coronary intervention \[PCI\]) or \>2x normal (spontaneous) with elevated CK-MB, or troponin \>3x normal (peri-PCI) or \>2x normal (spontaneous) plus one of the following: ECG changes indicating new ischemia (new ST-T changes/left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar criteria for MI post bypass graft surgery, with CK-MB or troponin \>5x normal
Query!
Timepoint [24]
0
0
12 months
Query!
Secondary outcome [25]
0
0
Target Lesion Revascularization (TLR)
Query!
Assessment method [25]
0
0
Target lesion revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Query!
Timepoint [25]
0
0
30 days
Query!
Secondary outcome [26]
0
0
Target Lesion Revascularization (TLR)
Query!
Assessment method [26]
0
0
TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Query!
Timepoint [26]
0
0
6 months
Query!
Secondary outcome [27]
0
0
Target Lesion Revascularization (TLR)
Query!
Assessment method [27]
0
0
TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.
Query!
Timepoint [27]
0
0
12 months
Query!
Secondary outcome [28]
0
0
Target Vessel Revascularization (TVR)
Query!
Assessment method [28]
0
0
Target vessel revascularization is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Query!
Timepoint [28]
0
0
30 days
Query!
Secondary outcome [29]
0
0
Target Vessel Revascularization (TVR)
Query!
Assessment method [29]
0
0
TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Query!
Timepoint [29]
0
0
6 months
Query!
Secondary outcome [30]
0
0
Target Vessel Revascularization (TVR)
Query!
Assessment method [30]
0
0
TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.
Query!
Timepoint [30]
0
0
12 months
Query!
Secondary outcome [31]
0
0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
Query!
Assessment method [31]
0
0
DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Query!
Timepoint [31]
0
0
24 hours
Query!
Secondary outcome [32]
0
0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
Query!
Assessment method [32]
0
0
DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Query!
Timepoint [32]
0
0
>24 hr-30 days
Query!
Secondary outcome [33]
0
0
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
Query!
Assessment method [33]
0
0
DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).
Query!
Timepoint [33]
0
0
>30 days-1 year
Query!
Secondary outcome [34]
0
0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)
Query!
Assessment method [34]
0
0
See above for definitions of MI and TVR
Query!
Timepoint [34]
0
0
30 days
Query!
Secondary outcome [35]
0
0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)
Query!
Assessment method [35]
0
0
See above for definitions of MI and TVR.
Query!
Timepoint [35]
0
0
6 months
Query!
Secondary outcome [36]
0
0
Composite of All Death, All Myocardial Infarction (MI), All Target Vessel Revascularization (TVR)
Query!
Assessment method [36]
0
0
See above for definitions of MI and TVR.
Query!
Timepoint [36]
0
0
12 months
Query!
Secondary outcome [37]
0
0
Clinical Procedural Success
Query!
Assessment method [37]
0
0
Defined as mean lesion diameter stenosis \<30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital myocardial infarction (MI), target vessel revascularization (TVR), or cardiac death
Query!
Timepoint [37]
0
0
In hospital
Query!
Secondary outcome [38]
0
0
Acute Technical Success
Query!
Assessment method [38]
0
0
Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent
Query!
Timepoint [38]
0
0
Acute-At time of index procedure
Query!
Eligibility
Key inclusion criteria
* Patient must be at least 18 years of age
* Patient (or legal guardian) understands study requirements and treatment procedures and provides written informed consent before any study-specific tests or procedures are performed
* For patients less than 20 years of age enrolled at a Japanese site, patient and patient's legal representative must provide written informed consent before any study-specific tests or procedures are performed
* Patient is eligible for percutaneous coronary intervention (PCI)
* Patient has documented stable angina pectoris or documented silent ischemia; or unstable angina pectoris
* Patient is an acceptable candidate for coronary artery bypass grafting (CABG)
* Patient has a left ventricular ejection fraction (LVEF) >=30% as measured within 30 days prior to enrollment
* Patient is willing to comply with all protocol-required follow-up evaluations
Angiographic Inclusion Criteria (visual estimate):
- Target lesion must be a de novo lesion located in a native coronary artery with a visually estimated reference vessel diameter (RVD) >=2.50 mm and <=4.25 mm. Target lesion length must measure (by visual estimate) <=24 mm. Target lesion must be in a major coronary artery or branch with visually estimated stenosis >=50% and <100% with Thrombolysis in Myocardial Infarction (TIMI) flow >1.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute myocardial infarction (MI)
* Patient has had a known diagnosis of recent MI (ie, within 72 hours prior to index procedure) and has elevated enzymes at time of index procedure as follows.
* Patients are excluded if any of the following criteria are met at time of the index procedure.
* If creatine kinase-myoglobin band (CK-MB) >2× upper limit of normal (ULN), the patient is excluded regardless of CK Total.
* If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.
* If CK Total/CK MB are not used and Troponin is, patients are excluded if the following criterion is met at time of index procedure.
* Troponin >1× ULN with at least one of the following.
* Patient has ischemic symptoms and ECG changes indicative of ongoing ischemia (eg, >1 mm ST segment elevation or depression in consecutive leads or new left bundle branch block [LBBB]);
* Development of pathological Q waves in the ECG; or
* Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK MB (or Troponin if CK Total/CK MB are not used) must be documented prior to enrolling/randomizing the patient.
* Patient has received an organ transplant or is on a waiting list for an organ transplant
* Patient is receiving or scheduled to receive chemotherapy within 30 days before or after index procedure
* Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
* Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin, coumadin) for indications other than acute coronary syndrome
* Patient has platelet count <100,000 cells/mm3 or >700,000 cells/mm3
* Patient has white blood cell (WBC) count <3,000 cells/mm3
* Patient has documented or suspected liver disease, including laboratory evidence of hepatitis
* Patient is on dialysis or has known renal insufficiency (ie, estimated creatinine clearance <50 ml/min by the Cockcroft Gault formula, or [(140-age)*lean body weight (in kg)]/[plasma creatinine (mg/dl)*72])
* Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions
* Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol
* Target vessel(s) or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to index procedure
* Target vessel(s) has been treated within 10 mm proximal or distal to target lesion (by visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) at any time prior to index procedure
* Non-target vessel or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to index procedure
* Planned or actual target vessel(s) treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter immediately prior to stent placement
* Planned PCI or CABG after index procedure
* Patient previously treated at any time with coronary intravascular brachytherapy
* Patient has a known allergy to the study stent system or protocol-required concomitant medications (eg, stainless steel, platinum, cobalt, chromium, nickel, tungsten, acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot be adequately premedicated
* Patient has active peptic ulcer or active gastrointestinal (GI) bleeding
* Patient has one of the following.
* Other serious medical illness (eg, cancer, congestive heart failure) that may reduce life expectancy to less than 24 months
* Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)
* Planned procedure that may cause non-compliance with protocol or confound data interpretation
* Patient is participating in another investigational drug or device clinical trial that has not reached its primary endpoint
* Patient intends to participate in another investigational drug or device clinical trial within 12 months after index procedure
* Patient with known intention to procreate within 12 months after index procedure (Women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure.)
* Patient is a woman who is pregnant or nursing (A pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)
* Patient has more than 2 target lesions, or more than 1 target lesion and 1 non-target lesion, which will be treated during the index procedure
Angiographic Exclusion Criteria (visual estimate):
* Target lesion meets any of the following criteria:
* Aorto-ostial location (ie, lesion located within 5 mm of ostium by visual estimate)
* Left main location
* Located within 5 mm of origin of the left anterior descending (LAD) coronary artery or left circumflex (LCX) coronary artery by visual estimate
* Located within a saphenous vein graft or arterial graft
* Will be accessed via a saphenous vein graft or arterial graft
* Involves a side branch >=2.0 mm in diameter by visual estimate
* Involves a clinically significant side branch <2.0 mm in diameter by visual estimate that has a clinically significant stenosis at the ostium
* TIMI flow 0 (total occlusion) or TIMI flow 1 prior to wire crossing
* Excessive tortuosity proximal to or within the lesion
* Extreme angulation proximal to or within the lesion
* Target lesion and/or target vessel proximal to the target lesion is moderately to severely calcified by visual estimate
* Restenotic from previous intervention
* Thrombus, or possible thrombus, present in target vessel
* Non-target lesion to be treated during the index procedure meets any of the following criteria:
* Located within the target vessel
* Located within a bypass graft (venous or arterial)
* Left main location
* Chronic total occlusion
* Involves a complex bifurcation (eg, bifurcations requiring treatment with more than 1 stent)
* Restenotic from previous intervention
* Patient has unprotected left main coronary artery disease (>50% diameter stenosis)
* Patient has protected left main coronary artery disease and a target lesion in the LAD or LCX
* Patient has an additional clinically significant lesion(s) in target vessel for which an intervention within 12 months after the index procedure is likely to be required
* Patient has 2 target lesions in the same vessel that are separated by less than 15 mm (by visual estimate) Note: Multiple focal stenoses will be considered as a single lesion if they can be completely covered with 1 stent.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1530
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment hospital [2]
0
0
St. Vincent's Hospital - Fitzroy
Query!
Recruitment hospital [3]
0
0
Royal Perth Hospital - Perth
Query!
Recruitment hospital [4]
0
0
The Prince Charles Hospital - Queensland
Query!
Recruitment postcode(s) [1]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [2]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [3]
0
0
6000 - Perth
Query!
Recruitment postcode(s) [4]
0
0
4032 - Queensland
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maine
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Mississippi
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Missouri
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Nebraska
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New Jersey
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New York
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
North Carolina
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Ohio
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Oklahoma
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Oregon
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Pennsylvania
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
South Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Tennessee
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Texas
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Virginia
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Washington
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Wisconsin
Query!
Country [33]
0
0
Austria
Query!
State/province [33]
0
0
Vienna
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Antwerpen
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Genk
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Gent
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Leuven
Query!
Country [38]
0
0
Denmark
Query!
State/province [38]
0
0
Aarhus
Query!
Country [39]
0
0
Denmark
Query!
State/province [39]
0
0
Copenhagen
Query!
Country [40]
0
0
Finland
Query!
State/province [40]
0
0
Oulu
Query!
Country [41]
0
0
Finland
Query!
State/province [41]
0
0
Tampere
Query!
Country [42]
0
0
Finland
Query!
State/province [42]
0
0
Turku
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Besancon
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Bordeaux
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Massy
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Montpellier
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Toulouse
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Bad Nauheim
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Bad Oeynhausen
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Bad Segeberg
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Berlin
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Heidelberg
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Leipzig
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Fukuoka
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Hokkaido
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Kanagawa
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Tokyo
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Osaka
Query!
Country [59]
0
0
Latvia
Query!
State/province [59]
0
0
Riga
Query!
Country [60]
0
0
Malaysia
Query!
State/province [60]
0
0
Sarawak
Query!
Country [61]
0
0
Malaysia
Query!
State/province [61]
0
0
Kuala Lumpur
Query!
Country [62]
0
0
Netherlands
Query!
State/province [62]
0
0
Alkmaar
Query!
Country [63]
0
0
Netherlands
Query!
State/province [63]
0
0
Breda
Query!
Country [64]
0
0
Netherlands
Query!
State/province [64]
0
0
Eindhoven
Query!
Country [65]
0
0
Netherlands
Query!
State/province [65]
0
0
Nieuwegein
Query!
Country [66]
0
0
New Zealand
Query!
State/province [66]
0
0
Auckland
Query!
Country [67]
0
0
New Zealand
Query!
State/province [67]
0
0
Wellington
Query!
Country [68]
0
0
Poland
Query!
State/province [68]
0
0
Bydgoszcz
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Krakow
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Warsaw
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Wroklaw
Query!
Country [72]
0
0
Portugal
Query!
State/province [72]
0
0
Carnaxide
Query!
Country [73]
0
0
Singapore
Query!
State/province [73]
0
0
Singapore
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
England
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Ireland
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Clydebank
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boston Scientific Corporation
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions. This clinical trial compares outcomes in patients treated with PROMUS Element to those in patients treated with a different everolimus-eluting coronary stent. The lesions are of average length in average-sized vessels ("workhorse"). A companion sub-trial evaluates outcomes in smaller vessels (SV) and another sub-trial evaluates outcomes in longer lesions (LL).
Query!
Trial website
https://clinicaltrials.gov/study/NCT00823212
Query!
Trial related presentations / publications
Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Allocco DJ, Dawkins KD; PLATINUM Trial Investigators. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol. 2011 Apr 19;57(16):1700-8. doi: 10.1016/j.jacc.2011.02.016. Epub 2011 Apr 4. Kelly CR, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, Hagiwara N, Rabinowitz A, Carrie D, Pompili V, Bouchard A, Saito S, Allocco DJ, Dawkins KD, Stone GW. Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease: 5-Year Results From the PLATINUM Trial. JACC Cardiovasc Interv. 2017 Dec 11;10(23):2392-2400. doi: 10.1016/j.jcin.2017.06.070.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Peter M Maurer, MPH
Query!
Address
0
0
Boston Scientific Corporation
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
Query!
No/undecided IPD sharing reason/comment
The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-US/data-sharing-requests.html).
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Stone GW, Teirstein PS, Meredith IT, Farah B, Dubo...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00823212